Peptides - Compound guides
AOD-9604
AOD-9604 is a fragment of human growth hormone developed as an anti-obesity drug whose human trials largely failed to show meaningful weight loss versus placebo.
AOD-9604 is a short synthetic peptide corresponding to a fragment near the tail end of the human growth hormone molecule, with a small modification at one end. The idea behind it came from work suggesting that growth hormone's effect on fat breakdown might be located in one specific part of the molecule, separate from the parts responsible for growth hormone's effects on growth and on blood glucose. If that were true, a fragment could in principle reproduce the fat-related effect without the rest of growth hormone's activity. The compound was developed in Australia and taken into human obesity trials on that basis.
AOD-9604 is included here as a case study in what happens when a plausible mechanism does not survive contact with human trial data. It is not an approved medicine in the UK or anywhere else, and its clinical development for obesity was not successful.
How it works
To place AOD-9604 in context it helps to understand the incretin system that dominates modern obesity pharmacology, because AOD-9604 is not part of it. GLP-1 and GIP are gut hormones released when food is eaten. They act on their own receptors to prompt glucose-dependent insulin release from the pancreas, slow the rate at which the stomach empties, and signal to appetite-regulating regions of the brain to produce satiety. Drugs that agonise those receptors reduce food intake, and that reduction in intake is the main reason they change body weight. This is the well-characterised pathway that licensed weight-management medicines work through.
AOD-9604 does none of that. It is not an incretin, it does not bind GLP-1 or GIP receptors, and it does not act on the appetite pathway. The proposed mechanism was instead peripheral and metabolic: laboratory and rodent work reported that the fragment stimulated lipolysis, the breakdown of stored triglyceride in fat cells, and inhibited lipogenesis, the laying down of new fat, apparently without acting through the growth hormone receptor in the way full growth hormone does and without the effects on insulin sensitivity that growth hormone can cause. Later work suggested the effect might involve beta-3 adrenergic signalling in adipose tissue. Even in the preclinical literature this mechanism was never fully resolved, and it is important to be clear that most of the supportive work was in cells and in rodents, which are a poor guide to human fat metabolism.
What the research actually shows
AOD-9604 did reach human trials, which is more than most compounds discussed in this area, and this is where the story becomes instructive. A randomised, double-blind, placebo-controlled trial in overweight and obese adults, published in 2004, tested several dose levels against placebo over 12 weeks and reported greater weight reduction in the pooled treated participants than in the placebo group. That early result generated considerable interest.
The larger and longer follow-up study did not confirm it. A subsequent randomised, double-blind, placebo-controlled trial in obese adults ran for 24 weeks with body weight change as the primary endpoint. It failed to show a statistically significant difference in weight loss between AOD-9604 and placebo. The developer discontinued the obesity programme on the basis of those results. This is the central finding a reader should take away: the compound was tested properly in humans, at the stage of development where efficacy is meant to be demonstrated, and the efficacy was not there.
Subsequent interest in AOD-9604 shifted to entirely different proposed uses, including cartilage and osteoarthritis research, again with limited human evidence. The compound also has a history in sports regulation, having been the subject of a high-profile Australian sports doping investigation. None of this changes the obesity picture. Its evidence grade is best described as early-human with a failed primary outcome - the strongest kind of negative evidence there is, because a well-run placebo-controlled trial that finds nothing is a genuine answer, not an absence of information.
Risks, side effects and what is still unknown
- In the published trials AOD-9604 was generally reported as well tolerated over the periods studied, but a drug that does not work cannot have a favourable risk-benefit ratio, because there is no benefit side to weigh anything against.
- No long-term human safety data exist. The trials were months long, involved limited numbers of participants and were stopped when efficacy failed, so there is no basis for statements about safety over years.
- It is not licensed as a medicine anywhere, so no regulator has assessed its safety dossier and no product information or contraindication list exists for it.
- Material sold online under this name has no assurance of identity, purity, sterility or dose. Analyses of peptides sold outside the regulated supply chain have repeatedly found products that do not match their labels, including wrong contents and contamination.
- Claims made for it in marketing - fat loss, joint repair, recovery - go substantially beyond what the human trial data support, and readers should treat the gap between the marketing and the trial record as the most informative thing about the compound.
Legal status in the UK
AOD-9604 is not approved as a medicine by the MHRA, the European Medicines Agency or the US Food and Drug Administration. There is no licensed AOD-9604 product, and consequently no lawful route by which it is supplied to a person in the UK as a medicine. Any material offered for sale online under this name sits entirely outside the regulated supply chain, with none of the identity, purity, sterility or dose assurances that licensing provides. A "research use only" label on a vial is a disclaimer by the seller, not a mark of quality or of legality for use in a person. AOD-9604 has been the subject of anti-doping proceedings and is prohibited in sport under World Anti-Doping Agency rules for athletes subject to testing.
For contrast, and to make the regulatory landscape clear: semaglutide and tirzepatide, the incretin drugs described elsewhere in this course, are licensed prescription-only medicines available in the UK only on prescription after clinical assessment and dispensed by a registered pharmacy. That is what a regulated route looks like. AOD-9604 has no such route at all.
This page is educational information only and is not medical advice. AOD-9604 is not an approved medicine anywhere and its human obesity trials did not demonstrate meaningful weight loss. Nothing here is a suggestion to obtain or use it. Questions about weight or metabolic health belong with a qualified healthcare professional.
Metabolic and incretin compounds
Start with the overview: How research peptides are grouped into families
Further reading
Sources for this classroom
Educational content only. Not medical advice, diagnosis or treatment. Always consult a qualified healthcare professional before changing your health regimen.
